News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
116 Results
Type
Article (1)
Company Profile (1)
Press Release (114)
Section
Business (38)
Deals (4)
Drug Development (14)
FDA (2)
News (54)
Tag
2024 Genetown Standard (1)
Alliances (1)
Approvals (2)
Biotechnology (1)
Clinical research (5)
Data (2)
Duchenne muscular dystrophy (2)
Earnings (16)
Events (39)
Executive appointments (1)
FDA (3)
Featured Employer (1)
Healthcare (8)
IPO (4)
People (20)
Phase I (4)
Phase II (5)
Phase III (1)
Preclinical (8)
Startups (1)
United States (22)
Date
Last 30 days (2)
Last 365 days (29)
2025 (5)
2024 (31)
2023 (18)
2022 (19)
2021 (21)
2020 (15)
2019 (7)
116 Results for "Dyne_tx".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
February 3, 2025
·
1 min read
Press Releases
Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
January 9, 2025
·
1 min read
Press Releases
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET
January 9, 2025
·
1 min read
Press Releases
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
January 21, 2025
·
6 min read
Press Releases
Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026
January 13, 2025
·
15 min read
Genetown
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
Dyne Therapeutics, Inc today announced three poster presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference being held March 19-22, 2023, in Dallas, TX, and virtually.
March 20, 2023
·
9 min read
Press Releases
Dyne Therapeutics to Present at Upcoming Investor Conferences
November 8, 2024
·
1 min read
Press Releases
Dyne Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines Conference
September 24, 2024
·
1 min read
Press Releases
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
October 9, 2024
·
8 min read
Business
Dyne Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
August 29, 2024
·
1 min read
1 of 12
Next
